The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.
Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA ...
The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.
Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...
The FDA has accepted Merck's (NYSE:MRK) supplemental New Drug Application with priority review for its drug Welireg, also known as belzutifan, for the treatment of a rare type of adrenal gland tumors.
ABSTRACT: Pheochromocytoma (PHEO) is a rare endocrine tumor from the chromaffin cells in the adrenomedullary gland and sympathetic/parasympathetic ganglia, secreting ...
A review of the literature and report of one institution's experience. Medicine (Baltimore) 1991; 70:46. Ulchaker, JC, Goldfarb, DA, Bravo, EL, Novick, AC. Successful outcomes in pheochromocytoma ...